Obamacare insurers ask for second-highest premiums increase in nearly a decade

Health insurers in the Obamacare marketplace are requesting median premium rate increases of 14% for 2027 (vs 2026 rates), the second-highest proposed jump since 2018. KFF attributes the pressure to higher-risk/sicker enrollees, expected +4% premium impact from a worsening health mix, plus inflation in broader economic costs, higher medication expenses, and increased provider consolidation. Obamacare enrollment is down 13% in 2026 to 19.2M (from 22.1M in 2025) as pandemic-era extra subsidies expired, with premiums up 58% in 2026 and deductibles rising about $1,000 per person. Insurer filings (77 insurers across 16 states and DC) imply premiums could rise more than 33% from 2025 to 2027, with major players flagging elevated medical costs.

Analysis

The market mechanism here is less “higher premiums = better insurer profits” and more “higher premiums accelerate the death spiral if subsidies and healthy enrollment keep weakening.” For exchange-heavy carriers, the first-order benefit of repricing is likely offset by a worse risk pool, higher administrative friction, and political scrutiny that can compress forward multiples before the earnings benefit shows up. The real winners are the carriers with either minimal ACA exposure or enough scale/diversification to let them walk away from underpriced books; the losers are the names still dependent on exchange membership for growth and operating leverage.

On a 1-3 month horizon, the key catalyst is not the filing itself but state approval and, more importantly, how aggressively managements talk about retention assumptions and 2027 margin guardrails on upcoming calls. If regulators trim requested rates, the spread between medical inflation and approved premiums becomes the problem, not the headline increase. On a 6-18 month horizon, persistent subsidy weakness would push more healthy lives out of the pool, which should force further retrenchment by smaller players and reward disciplined exits over volume growth.

Contrarian takeaway: the consensus may be too quick to treat this as broadly bullish for managed care. It is actually a relative-quality event—good for insurers with limited exchange exposure, but potentially bearish for the weakest exchange books because the higher sticker price can destroy the very membership base needed to make the pricing work. CVS’s exit looks more like disciplined capital allocation than retreat; CNC remains the more exposed earnings-risk story, while UNH should be best insulated due to diversification and balance-sheet flexibility.

Key Decisions for Investors

• Relative value: long UNH / short CNC over the next 1-3 months into exchange rate-approval headlines; best risk/reward if the market keeps treating all managed care as one trade. Falsify if UNH flags meaningful exchange losses or CNC shows unusually strong retention on 3Q commentary.
• Short CNC on strength ahead of open-enrollment season; the downside is that premium increases may look supportive at first, but the thesis is that adverse selection and membership erosion show up with a lag. Cover if CNC guides to stable exchange MLR or better-than-expected marketplace membership.
• Keep CVS as a watchlist name rather than a momentum long: the exchange exit reduces direct ACA downside, so any selloff driven by sector contagion may create a better entry in the next 4-8 weeks. The thesis fails if Aetna management signals broader underwriting deterioration outside the exchange book.
• Pair trade alternative: long XLV / short IHF if the market starts pricing in broader healthcare inflation without distinguishing diversified names from exchange-sensitive names. This works best over 1-3 months if state approvals come in below requested rates.
• Do not force an options expression until July 15 filings are fully in and management commentary clarifies retention assumptions; the cleaner trigger is 3Q enrollment data, not the premium headline itself.